Kazia Therapeutics Limited American Depositary Shares KZIA
$7.98
-1.24%
at last close
Market Cap$125.63 million
P/E Ratio—
Div Yield—
Volume151.0K
52-Week Range
$4.86$17.40
Analyst Ratings
- Consensus
- Buy — 8 Buy · 0 Hold · 0 Sell (8 analysts)
- Avg. Price Target
- $29.50 (+269.7% upside)
Key Stats
- Today's Range
- $7.70 – $8.55
- 50-Day Range
- $6.62 – $17.18
- 52-Week Range
- $4.86 – $17.40
- Volume
- 151K shs
- Average Volume
- 222K shs
- Market Cap
- $125.63 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.04%
- Days to Cover
- 1.00
About Kazia Therapeutics Limited American Depositary Shares
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
Related Stocks
Compare head-to-head: KZIA vs LLY·KZIA vs JNJ·KZIA vs ABBV·KZIA vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.